Publications by authors named "Stephane Bogen"

Claim this Profile
P
Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
Yuan Tian, Brian R Lahue, Yao Ma, Latha G Nair, Weidong Pan, Stéphane L Bogen

Bioorg Med Chem Lett· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.
Chunhui Huang, Christian Fischer, Michelle R Machacek, Stephane Bogen, Tesfaye Biftu

ACS Med Chem Lett· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of : an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.
Michael H Reutershan, Michelle R Machacek, Michael D Altman, Stephane Bogen, Mingmei Cai

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides.
Frank Bennett, Alexei V Buevich, Hsueh-Cheng Huang, Vinay Girijavallabhan, Angela D Kerekes, Stephane L Bogen

Bioorg Med Chem Lett· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
Yuan Tian, Yao Ma, Craig R Gibeau, Brian R Lahue, Gerald W Shipps, Stéphane L Bogen

Bioorg Med Chem Lett· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2'-Modified Guanosine Analogs for the Treatment of HCV.
Vinay Girijavallabhan, Ashok Arasappan, Frank Bennett, Kevin Chen, Qun Dang, Stephane Bogen

Nucleosides Nucleotides Nucleic Acids· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
Stéphane L Bogen, Weidong Pan, Craig R Gibeau, Brian R Lahue, Yao Ma

ACS Med Chem Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
Yao Ma, Brian R Lahue, Craig R Gibeau, Gerald W Shipps, Stéphane L Bogen

ACS Med Chem Lett· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Weidong Pan, Brian R Lahue, Yao Ma, Latha G Nair, Gerald W Shipps, Stéphane L Bogen

Bioorg Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.
Ashok Arasappan, Frank Bennett, Stephane L Bogen, Srikanth Venkatraman, Melissa Blackman

ACS Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Francisco Velázquez, Mousumi Sannigrahi, Frank Bennett, Raymond G Lovey, Ashok Arasappan, Stéphane Bogen

J Med Chem· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
Frank Bennett, Yuhua Huang, Siska Hendrata, Raymond Lovey, Stephane L Bogen

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
Latha G Nair, Stephane Bogen, Sumei Ruan, Weidong Pan, Russel Pike

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
Stéphane L Bogen, Ashok Arasappan, Francisco Velazquez, Melissa Blackman, Regina Huelgas

Bioorg Med Chem· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
Latha G Nair, Mousumi Sannigrahi, Stephane Bogen, Patrick Pinto, Kevin X Chen

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Srikanth Venkatraman, Mellissa Blackman, Wanli Wu, Latha Nair, Ashok Arasappan, Stéphane Bogen

Bioorg Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Stéphane L Bogen, Weidong Pan, Sumei Ruan, Latha G Nair, Ashok Arasappan

J Med Chem· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Ashok Arasappan, Angela I Padilla, Edwin Jao, Frank Bennett, Stephane L Bogen

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
Kevin X Chen, Latha Nair, Bancha Vibulbhan, Weiying Yang, Ashok Arasappan, Stephane L Bogen

J Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
Francisco Velázquez, Srikanth Venkatraman, Melissa Blackman, Patrick Pinto, Stéphane Bogen

J Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
Srikanth Venkatraman, Francisco Velazquez, Wanli Wu, Melissa Blackman, Kevin X Chen, Stephane Bogen

J Med Chem· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034.
Vincent Madison, Andrew J Prongay, Zhuyan Guo, Nanhua Yao, John Pichardo, Stephane L Bogen

J Synchrotron Radiat· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.
Cheng Li, Latha Nair, Tongtong Liu, Fangbiao Li, John Pichardo, Stephane Bogen

Biochem Pharmacol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of resistance mutations against HCV ketoamide protease inhibitors.
Xiao Tong, Stephane Bogen, Robert Chase, V Girijavallabhan, Zhuyan Guo

Antiviral Res· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Andrew J Prongay, Zhuyan Guo, Nanhua Yao, John Pichardo, Thierry Fischmann, Stephane L Bogen

J Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis